IP Library › Granted Patent US 12,674,146
Granted Patent B2
US 12,674,146 · App. 18/035,149 · Granted Jul 7, 2026

Modified uricase and uses thereof

Inventors: Ilya Ruderfer (Carmiel, IL); Yakir Nataf (Kiryat Motzkin, IL); Gil Arvatz (Kfar Tavor, IL); Uri Hanania (Carmiel, IL); Tamar Ariel (Manof, IL); Shelly Rozen (Yuvalim, IL); Yael Hayon (Tel Aviv, IL)
Assignee: Protalix Ltd.
C12N9/0048A61K38/44C12Y107/03003
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,674,146
App. No.
18/035,149
Filed
May 3, 2023
Granted
Jul 7, 2026
Kind
B2
Art Unit
1657
USPC
424/94.4
Abstract

A modified uricase is described herein, as well as a method of reducing a level of uric acid by contacting a medium with the modified uricase. The modified uricase comprises a uricase polypeptide crosslinked by at least one bifunctional linking moiety that comprises a poly(alkylene glycol) moiety. A molecular weight of the bifunctional linking moiety is from about 1.5 kDa to about 4 kDa, and/or the modified uricase comprises a plurality of polypeptides having the amino acid sequence SEQ ID NO: 2. Further described is a polypeptide having the amino acid sequence SEQ ID NO: 2. A process of preparing the modified uricase is also described, comprising contacting the polypeptide with a crosslinking agent that comprises a poly(alkylene glycol) moiety and at least two aldehyde groups, to obtain a conjugate; and contacting the conjugate with a reducing agent.

Claims (14)

1 . A modified uricase comprising a plurality of uricase polypeptides having the amino acid sequence SEQ ID NO: 2, crosslinked by at least one bifunctional linking moiety that comprises a poly(alkylene glycol) moiety, wherein a molecular weight of said bifunctional linking moiety is in a range of from about 1.5 kDa to about 4 kDa, and wherein said at least one bifunctional linking moiety is covalently attached to a lysine residue of a uricase polypeptide having the amino acid sequence SEQ ID NO: 2.

2 . The modified uricase of claim 1 , wherein said molecular weight of said bifunctional linking moiety is in a range of from about 2 kDa to about 4 kDa.

3 . The modified uricase of claim 1 , wherein said at least one bifunctional linking moiety comprises an alkylene group covalently attached to a nitrogen atom of an amine group comprised by a side chain of said lysine residue of the uricase polypeptide.

4 . The modified uricase of claim 1 , wherein said uricase polypeptide is attached to an average of at least 8 of said bifunctional linking moiety and/or wherein at least 30% of lysine residue side chains in the uricase polypeptide having the amino acid sequence SEQ ID NO: 2 are covalently attached to said at least one bifunctional linking moiety.

5 . The modified uricase of claim 1 , being in a form of a crosslinked tetramer.

6 . The modified uricase of claim 1 , wherein said uricase polypeptide is a plant recombinant polypeptide.

7 . The modified uricase of claim 1 , being characterized by a plasma half-life in rats of at least 50 hours.

8 . A method of treating a disease or disorder in which uricase activity is beneficial and/or a disease or disorder associated with excessive uric acid levels, in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the modified uricase of claim 1 , thereby treating the disease or disorder.

9 . The method of claim 8 , said administering the modified uricase is at an interval of at least one week.

10 . The method of claim 9 , wherein administering the modified uricase is at a dosage of no more than 8 mg per month.

11 . A process of preparing the modified uricase of claim 1 , the process comprising:

(a) contacting said plurality of uricase polypeptides having the amino acid sequence SEQ ID NO: 2 with a crosslinking agent that comprises said poly(alkylene glycol) moiety, said crosslinking agent comprising at least two aldehyde groups, to thereby conjugate said plurality of uricase polypeptides having the amino acid sequence SEQ ID NO: 2 and said crosslinking agent; and

(b) contacting the plurality of uricase polypeptides having the amino acid sequence SEQ ID NO: 2 conjugated to said crosslinking agent with a reducing agent.

12 . A method of reducing a level of uric acid in a medium, the method comprising contacting the medium with the modified uricase of claim 1 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2023
From: RUDERFER, ILYA; NATAF, YAKIR; ARVATZ, GIL; HANANIA, URI; ARIEL, TAMAR; ROZEN, SHELLY; HAYON, YAEL
To: PROTALIX LTD.
Reel/Frame 065305/0608 →
Continuity (2)
Provisional Application 63108890 · Nov 3, 2020
Related Publication 20240002814A1 · Jan 4, 2024
References Cited (83)
US 4179337A · Davis et al. · 1979 [cited by applicant]
US 6913915B2 · Ensor et al. · 2005 [cited by applicant]
US 8188224B2 · Hartman et al. · 2012 [cited by applicant]
US 9885024B2 · Williams et al. · 2018 [cited by applicant]
US 20030166249A1 · Williams et al. · 2003 [cited by applicant]
US 20030195339A1 · Yamasaki · 2003 [cited by examiner]
US 20070274977A1 · Hartman et al. · 2007 [cited by applicant]
US 20080159976A1 · Hartman et al. · 2008 [cited by applicant]
US 20100050294A1 · Chen et al. · 2010 [cited by applicant]
US 20120240288A1 · Ye et al. · 2012 [cited by applicant]
US 20170189544A1 · Martinez et al. · 2017 [cited by applicant]
US 20190309269A1 · Hoffman et al. · 2019 [cited by applicant]
US 20220023394A1 · Botson · 2022 [cited by applicant]
US 20230211002A1 · Cho · 2023 [cited by examiner]
US 20230374447A1 · Hanania · 2023 [cited by applicant]
EP 2684950 · 2014 [cited by applicant]
JP 5599189 · 1980 [cited by applicant]
JP 2002524053 · 2002 [cited by applicant]
JP 2007537992 · 2007 [cited by applicant]
JP 2008535500 · 2008 [cited by applicant]
JP 2016510601 · 2016 [cited by applicant]
JP 2020506932 · 2020 [cited by applicant]
WO WO0007629 · 2000 [cited by applicant]
WO WO2011107990 · 2011 [cited by applicant]
WO WO2011107991 · 2011 [cited by applicant]
WO WO2011107992 · 2011 [cited by applicant]
WO WO2011107992A2 · 2011 [cited by examiner]
WO WO2015054602 · 2015 [cited by applicant]
WO WO2016187026 · 2016 [cited by applicant]
WO WO2018169811 · 2018 [cited by applicant]
WO WO2019010369 · 2019 [cited by applicant]
WO WO2019222379 · 2019 [cited by applicant]
WO WO2022074646 · 2022 [cited by applicant]
WO WO2022097141 · 2022 [cited by applicant]
Najjari, Abbas, et al. “The effective control of hyperuricemia in cancer patients: a new recombinant conjugated variant of urate oxidase.” Asian Pacific Journal of Cancer Prevention: APJCP 22.2 (2021): 627. (Year: 2021). [cited by examiner]
Xue, Ya-Ping, Cheng-Hao Cao, and Yu-Guo Zheng. “Enzymatic asymmetric synthesis of chiral amino acids.” Chemical Society Reviews 47.4 (2018): 1516-1561. (Year: 2018). [cited by examiner]
International Preliminary Report on Patentability May 19, 2023 From the International Bureau of WIPO Re. Application No. PCT IL2021/051305. (7 Pages). [cited by applicant]
International Preliminary Report on Patentability Apr. 20, 2023 From the International Bureau of WIPO Re. Application No. PCT IL2021/051194. (9 Pages). [cited by applicant]
International Search Report and the Written Opinion Dated Mar. 18, 2022 From the International Searching Authority Re. Application No. PCT/IL2021/051305. (14 Pages). [cited by applicant]
International Search Report and the Written Opinion Dated Jan. 26, 2022 From the International Searching Authority Re. Application No. PCT/IL2021/051194. (16 Pages). [cited by applicant]
Baraf et al. “Tophus Burden Reduction With Peglioticase: Results From Phase 3 Randomized Trials and Open-Label Extension in Patients With Chronic Gout Refractory to Conventional Therapy”, Arthritis Research & Therapy, 1… [cited by applicant]
Chua et al. “Use of Polyethylene Glycol-Modified Uricase (PEG-Uricase) to Treat Hyperuricemia in A Patient With Non-Hodgkin Lymphoma”, Annals of Internal Medicine, 109: 114-117, Jul. 15, 1988. [cited by applicant]
Crane et al. “Biological Activities of Uric Acid in Infection Due to Enteropathogenic and Shiga-Toxigenic [cited by applicant]
Crane et al. “Pro-Inflammatory Effects of Uric Acid in the Gastrointestinal Tract”, Immunological Investigations, 43(3): 255-266, Published Online Dec. 30, 2013. [cited by applicant]
D'Alessandro et al. “Trauma/Hemorrhagic Shock Instigates Aberrant Metabolic Flux Through Glycolytic Pathways, as Revealed by Preliminary 13C-Glucose Labeling Metabolomics”, Journal of Translational Medicine, 13(1): 253-… [cited by applicant]
Daxinger et al. “Unexpected Silencing Effects From T-DNA Tags in [cited by applicant]
Deleris et al. “Hierarchical Action and Inhibition of Plant Dicer-Like Proteins in Antiviral Defense”, Science, 313(5783): 68-71, Published Online Jun. 1, 2006. [cited by applicant]
Gallego-Delgado et al. “A Surprising Role for Uric acid: The Inflammatory Malaria Response”, Current Rheumatology Report, 16(2): 401-1-401-10 Feb. 2014. [cited by applicant]
Ganson et al. Control of Hyperuricemia in Subjects With Refractory Gout, and Induction of antibody Against Poly(Ethylene Glycol) (PEG), in A Phase I Trial of Subcutaneous PEGylated Urate Oxidase, Arthritis Research & Th… [cited by applicant]
Garcia-Ruiz et al. “ [cited by applicant]
Hershfield et al. “Development of PEGylated Mammalian Urate Oxidase as A Therapy for Patients With Refractory Gout”, PEGylated Protein Drugs: Basic Science and Clinical Applications, p. 217-227, 2009. [cited by applicant]
Hershfield et al. “Induced and Pre-Existing Anti-Polyethylene Glycol Antibody in A Trial of Every 3-Week Dosing of Pegloticase for Refractory Gout, Including in Organ Transplant Recipients”, Arthritis Rescarch & Therapy… [cited by applicant]
Katsarou et al. “DCL-Suppressed Nicotiana Benthamiana Plants: Valuable Tools in Research and Biotechnology”, Molecular Plant Pathology, XP055878250, 20(3): 432-446, Published Online Dec. 19, 2018. [cited by applicant]
Kool et al. “An Unexpected Role for Uric Acid as An Inducer of T Helper 2 Cell Immunity to Inhaled Antigens and Inflammatory Mediator of Allergic Asthma”, Immunity, 34(4): 527-540, Apr. 22, 2011. [cited by applicant]
Koyama et al. “Cloning, Sequence Analysis, and Expression in [cited by applicant]
Liu et al. “Clinical and Basic Evaluation of the Prognostic Value of Uric Acid in Traumatic Brain Injury”, International Journal of Medical Sciences, 15(10): 1072-1082, Published Online Jun. 23, 2018. [cited by applicant]
Matsuo et al. “CRISPR/Cas9-Mediated Knockout of the RDR6 Gene in Nicotiana Benthamiana for Efficient Transient Expression of Recombinant Proteins”, Planta, XP055878256, 250(2): 463-473, Published Online May 7, 2019. [cited by applicant]
Matsuo et al. “Hyperuricemia in Acute Gastroenteritis Is Caused by by Decreased Urate Excretion Via ABCG2”, Scientific Reports, 6: 31003-1-31003-6, Aug. 30, 2016. [cited by applicant]
Matsuo et al. “Repression of the DCL2 and DCL4 Genes in Nicotiana Benthamiana Plants for the Transient Expression of Recombinant Proteins”, Journal of Bioscience and Bioengineering, XP085114986, 124(2): 215-220, Publish… [cited by applicant]
Nadeau-Vallee et al. “Sterile Inflammation and Pregnancy Complications: A Review”, Reproduction, 152(6): R277-R292, Published Online Sep. 27, 2016. [cited by applicant]
Nyborg et al. “A Therapeutic Uricase With Reduced Immunogenicity Risk and Improved Development Properties”, PLoS ONE, 11(12): e0167935-1-e0167935-23, Dec. 21, 2016. [cited by applicant]
Parent et al. “Respective Contributions of [cited by applicant]
Piancone et al. “Monosodium Urate Crystals Activate the Inflammasome in Primary Progressive Multiple Sclerosis”, Frontiers in Immunology, 9: 983-1-983-12, Published Online May 4, 2018. [cited by applicant]
Polydore et al. “Analysis of RDR1/RDR2/RDR6-Independent Small RNAs in [cited by applicant]
Qin et al. “Roles of Dicer-Like Proteins 2 and 4 in Intra- and Intercellular Antiviral Silencing”, Plant Physiology, 174(2): 1067-1081, Jun. 2017. [cited by applicant]
Richette et al. “Rasburicase for Tophaceous Gout Not Treatable With Allupurinol: An Exploratory Study”, The Journal of Rheumatology, 34(10): 2093-2098, Published Online Sep. 15, 2007. [cited by applicant]
Seta et al. “Post-Translational Regulation of the Dicing Activities of [cited by applicant]
Strand et al. “Improved Health-Related Quality of Life and Physical Function in Patients With Refractory Chronic Gout Following Treatmetn With Pegloticase: Evidence From Phase III Randomized Controlled Trials”, The Jour… [cited by applicant]
Sundy et al. “Efficacy and Tolerability of Pegloticase for the Treatment of Chronic Gout in Patients Refractory to Conventional Treatment. Two Randomized Controlled Trials”, Journal of American Medicial Association, JAM… [cited by applicant]
Sundy et al. “Reduction of Plasma Urate Levels Following Treatment With Multiple Doses in Pegloticase (Polyethylene Glycol-Conjugated Uricase) in Patients With Treatment-Failure Gout”, Arthritis & Rheumatism, 58(9): 288… [cited by applicant]
Suzuki et al. “RNAi-Mediated Down-Regulation of Dicer-Like 2 and 4 Changes the Response of ‘Moneymaker’ Tomato to Potato Spindle Tuber Viroid Infection From Tolerance to Lethal Systemic Necrosis, Accompanied by Up-Regul… [cited by applicant]
Veronese “Peptide and Protein PEGylation: A Review of Problems and Solutions”, Biomaterials, 22(5): 405-417, Mar. 2001. [cited by applicant]
Xie et al. “DICER-LIKE 4 Functions in Trans-Acting Small Interfering RNA Biogenesis and Vegetative Phase Change in [cited by applicant]
Yoshikawa et al. “A Pathway for the Biogenesis of Trans-Acting SiRNAs in [cited by applicant]
Zhang et al. “Anti-PEG Antibodies in the Clinic: Current Issues and Beyond PEGylation”, Journal of Controlled Release, 244(Pt.B): 184-193, Dec. 28, 2016. [cited by applicant]
Baraf et al. “The COMPARE Head-to-Head, Randomized Controlled Trial of SEL-212 (Pegadricase Plus Rapamycin-Containing Nanoparticle, ImmTOR™) Versus Pegloticase for Refractory Gout”, Rheumatology, p. 1-10, Advance Access… [cited by applicant]
Botson et al. “A Randomized, Placebo-Controlled Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings”, Arthritis & Rheumatology,… [cited by applicant]
ClinicalTrials “A Study to Evaluate the Safety, Tolerability, PK, and PD Properties of PRX-115 in Adult Volunteers With Elevated Uric Acid Levels”, ClinicaTrials.gov, ID NCT05745727, 10 P., Last Update Posted Nov. 18, 2… [cited by applicant]
Kivitz et al. “Phase 2 Dose-Finding Study in Patients With Gout Using SEL-212, A Novel PEGylated Uricase (SEL-037) Combined With Tolerogenic Nanoparticles (SEL-110)”, Rheumatology & Therapy, 10(4): 825-847, Published On… [cited by applicant]
Notice of Reason(s) for Rejection Dated Sep. 16, 2025 From the Japan Patent Office Re. Application No. 2023-526588 and Its Translation Into English. (8 Pages). [cited by applicant]
Official Action Dated Dec. 29, 2025 from the US Patent and Trademark Office Re. U.S. Appl. No. 18/429,649. (27 Pages). [cited by applicant]
Macovei et al. “Clinical and Epidemiological Aspects of Gout, A Dysmetabolic Disabling Disorder”, The Medical-Surgical Journal, 119 (1): 62-68, Mar. 31, 2015. [cited by applicant]
Sarawate et al. “Scrum Urate Levels and Gout Flares: Analysis from Managed Care Data”, Journal of Clinical Rheumatology, 12 (2): 61-65, Apr. 2006. [cited by applicant]